SCHEMBL13699664

SCHEMBL13699664

CC1CCN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
OPRL1 P41146 4/20 0.53
OPRM1 P35372 4/20 0.53
CHRM2 P08172 2/20 0.52
ADRA2A P08913 2/20 0.52
CHRM1 P11229 2/20 0.52
DRD1 P21728 2/20 0.52
DRD3 P35462 2/20 0.52
SLC6A3 Q01959 2/20 0.52
KCNH2 Q12809 2/20 0.52
CHRM4 P08173 1/20 0.52
CHRM5 P08912 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
CYP2D6 P10635 1/20 0.52
CHRM3 P20309 1/20 0.52
ADRA1D P25100 1/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
HRH1 P35367 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19083895 1.00 L3MBTL3 (0.53) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
SCHEMBL19083892 1.00 L3MBTL3 (0.53) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
SCHEMBL3457922 0.89 L3MBTL3 (0.61) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
SCHEMBL6843039 0.84 OPRM1 (0.53) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
Ammonia Solution, Strong SCHEMBL29274480 0.82 OPRM1 (0.52) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
SCHEMBL5745248 0.80 OPRL1 (0.51) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
SCHEMBL5746042 0.80 OPRL1 (0.51) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
SCHEMBL19075614 0.79 DPP4 (0.52) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
SCHEMBL19075528 0.79 DPP4 (0.52) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2
SCHEMBL18762175 0.78 SIGMAR1 (0.43) L3MBTL3L3MBTL1OPRL1OPRM1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090240066-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-7569599-B2 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-08-04 US disclosed
US-20070117988-A1 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI SANKYO COMPANY, LIMITED (JP) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117988-A1 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates RAP1A, RHOA, MGMT L3MBTL3 2636/4885L3MBTL1 3585/4885OPRL1 2680/4885
US-20090240066-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES RAP1A, RHOA, MGMT L3MBTL3 2636/4885L3MBTL1 3585/4885OPRL1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.